Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
Authors' conclusion
Previously documented associations between SAF and CVD, also found in our study, may be explained by the endophenotypes atherosclerosis and arterial stiffness, especially in men and individuals with diabetes or CKD, but not by hypertension. Longitudinal studies are needed to replicate these findings and to test if SAF is an independent risk factor or biomarker of CVD.
Study context
- Population
- Participants of the population-based Rotterdam Study; mean age 73 (SD 9) years, 57% women
- Participants
- 3,001 participants
- Exposure
- Skin AGEs measured as skin autofluorescence (SAF) and subclinical cardiovascular disease (CVD) endophenotypes
- Outcome
- Carotid plaques, carotid IMT, CAC, PWV and hypertension (endophenotypes)
Methodological detailspopulation-based
- Population-based
Main finding
As reported in the abstract
Associations of SAF (per 1-unit higher) with subclinical CVD endophenotypes
- Carotid plaques, OR
- 1.2 (0.92, 1.57) (CI)
- Higher max intima-media thickness (IMT), SD
- 0.08 (0.01, 0.15) (CI)
- Higher coronary artery calcification (CAC), OR
- 2.2 (1.39, 3.48) (CI)
- Higher pulse wave velocity (PWV), SD
- 0.09 (0.01, 0.16) (CI)
- Hypertension (not associated), OR
- 0.99 (0.81, 1.21) (CI)
Observational data: associations, not effects.
Further findings
Effect modification by sex, DM and chronic kidney disease (CKD)
- Associations with endophenotypes more pronounced in men and participants with diabetes or CKD, with significant interactions
Original publication
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study. Cardiovasc Diabetol. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →